Welcome to our dedicated page for Adma Biologics SEC filings (Ticker: ADMA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ADMA Biologics, Inc. (NASDAQ: ADMA) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, alongside AI-generated explanations to help interpret the information. ADMA is a U.S.-based, end-to-end commercial biopharmaceutical company focused on specialty plasma-derived biologics and other specialty biologics for immunodeficient patients and individuals at risk for certain infectious diseases.
Through this page, users can review ADMA’s current and historical SEC filings, including Form 8-K reports that announce material events such as quarterly financial results and business updates. For example, an 8-K dated November 5, 2025, references a press release detailing financial results for the quarter ended September 30, 2025 and a related business update. Filings such as 10-K annual reports and 10-Q quarterly reports (when available) typically contain detailed information on revenue composition, operating segments such as ADMA BioManufacturing and Plasma Collection Centers, risk factors, and descriptions of products like ASCENIV, BIVIGAM and NABI-HB.
Stock Titan’s platform enhances these documents with AI-powered summaries that highlight key points, helping readers quickly understand complex regulatory language. Users can also track real-time updates as new filings are posted to the SEC’s EDGAR system, and review insider transaction disclosures on forms such as Form 4 when they are filed, to see reported trades by company officers and directors.
This SEC filings hub is intended for investors and researchers who want a structured view of ADMA’s regulatory reporting, including its financial performance communications, capital structure updates, and disclosures related to its plasma-derived biologics portfolio and manufacturing operations.
ADMA Biologics director Lawrence P. Guiheen reported a mix of option exercises and charitable estate planning transactions. On March 13, 2026, he exercised stock options to acquire 30,000 shares of common stock at $3.66 per share, increasing his direct equity stake. On March 17, 2026, he made bona fide gifts totaling 60,000 shares of common stock, including 30,000 shares transferred directly and 30,000 shares gifted to the 2019 Guiheen Irrevocable Trust, over which he retains control but disclaims beneficial ownership except for any pecuniary interest. After these transactions, he holds 105,520 shares directly, with additional shares held indirectly through irrevocable trusts as described in the footnotes.
ADMA Biologics President and CEO Adam S. Grossman exercised stock options for 15,000 shares of common stock at $5.40 per share on March 16, 2026, then sold 21,000 shares of common stock at $15.16 per share in open-market transactions.
The filing shows these trades were effected under a Rule 10b5-1 trading plan entered into on November 14, 2025. After the transactions, Grossman holds 2,112,777 shares of ADMA Biologics common stock directly, while entities Areth, LLC and Hariden, LLC hold 1,143,426 and 580,957 shares indirectly associated with him.
ADMA Biologics submitted a Form 144 notice proposing the sale of Common Stock. The filing lists multiple blocks of restricted stock units scheduled to vest on specific dates, including 15,162 shares vesting 06/26/2024 and another 15,162 shares vesting 06/26/2025. The broker/agent listed is Fidelity Brokerage Services, LLC (10b5-1 Group).
ADMA Biologics COO and SVP, Compliance Kaitlin M. Kestenberg-Messina reported multiple stock transactions. She exercised stock options to acquire 10,096 shares of common stock at exercise prices ranging from $1.55 to $5.00 per share. In connection with restricted stock unit vesting, 14,294 shares were withheld to cover mandatory tax obligations, which did not involve open-market sales. She also transferred 91,266 shares and sold 10,096 shares of common stock at a weighted average price of $15.63 per share, both carried out under a court-approved divorce settlement. Following these transactions, she directly owned 466,600 shares of ADMA Biologics common stock.
ADMA Biologics President and CEO Adam S. Grossman reported tax-related share withholdings rather than market trades. On March 6–7, 2026, a total of 85,951 shares of Common Stock were withheld at $15.39 per share to satisfy mandatory tax obligations upon vesting of restricted stock units, as noted in the footnotes. After these withholdings, he directly held 2,118,777 shares of Common Stock. Separate holding entries show additional indirect ownership of 1,143,426 shares through Areth, LLC and 580,957 shares through Hariden, LLC, entities over which he has control roles.
ADMA Biologics submitted a Form 144 reporting proposed sales of Common Stock tied to option exercises, all dated 03/09/2026. The submission lists five exercise lots: 2,500, 1,250, 2,646, 1,525, and 2,175 shares, each described as "Stock Option Exercise" with the original grant dates shown.
ADMA Biologics director-affiliated funds reported open-market purchases of common stock. Entities associated with director Steve Elms bought a total of 14,000 ADMA shares, with 7,000 shares purchased on March 5, 2026 at a weighted average price of $15.67 per share and 7,000 shares on March 6, 2026 at a weighted average price of $15.39 per share.
The filing notes these shares are held by Aisling Capital II LP and Aisling Arcturus Partners, LP, and that Mr. Elms may be deemed a beneficial owner through his roles at Aisling entities while disclaiming beneficial ownership except to the extent of his pecuniary interest. Following these transactions, Aisling-related entities reported 2,045,730 shares, while Mr. Elms also directly holds 87,330 shares and 10,690 restricted stock units that are scheduled to fully vest on February 9, 2027, subject to continued service.
ADMA Biologics President and CEO Adam S. Grossman reported a tax-related share disposition tied to restricted stock unit vesting. On the transaction date, 54,858 shares of common stock were withheld at $15.18 per share to satisfy mandatory tax withholding obligations, and this was explicitly noted as not an open market sale.
After this withholding, Grossman directly owned 2,204,728 shares of ADMA common stock. He also had indirect ownership of 1,143,426 shares through Areth, LLC and 580,957 shares through Hariden, LLC, entities for which he is disclosed as a control person or managing member.
ADMA Biologics entered a $125 million accelerated share repurchase agreement with JPMorgan Chase Bank as part of its previously authorized $500 million share repurchase program. The company will fund the transaction with borrowings under its existing $225 million revolving credit facility.
ADMA expects to receive about 6.4 million shares of common stock around March 3, 2026, representing roughly 80% of the shares tied to this agreement, based on a closing share price of $15.57 on February 27, 2026. The final share count will depend on the average daily volume‑weighted average price over the ASR term and is expected to be settled within five months, which could result in ADMA receiving additional shares or delivering shares or cash at final settlement.
The company also outlined a 2026 capital return initiative targeting approximately $200 million, noting that, since the program’s May 2025 authorization, prior repurchases plus this ASR represent about $160 million of common stock repurchased. Management highlights sustained revenue growth, expanding margins and anticipated stronger cash flow as support for continuing to invest in growth while returning capital to stockholders.
ADMA Biologics CFO and Treasurer Terry Kohler filed an initial ownership report showing his equity stake in the company. He reported 91,166 stock options and 58,019 shares of common stock held directly. Footnotes explain these reflect previously granted stock options and restricted stock units that vest over four years.